Gedeon Richter is a multinational, European innovation-driven specialty pharmaceutical company established in 1901 in Hungary. During its continuous tradition, the company is continuously committed to quality and innovation.
Over two hundred products from Richter brand is available in more than 100 countries. Outside Hungary, the company has direct presence in 45 countries with five manufacturing units, 29 representative offices and 38 sales and wholesale companies.
Richter Gedeon Representative Office in Serbia is established in 2007.
Innovation and research of the original molecules are key elements of the company's strategy since its founding. Richter’s R&D base, today employs 1,000 people whereas some 10% of the turnover on an annual basis invests in research, innovation and development, which are key strategies for the future of the Company. Due to this fact, Gedeon Richter is among the most important pharmaceutical research centre in Central Eastern Europe.
The Company is commited to provide efficient, high-quality and affordable treatment with it’s original, generic and licensed drugs in almost every therapeutic area. The company focuses on developing and manufacturing central nervous system, cardiovascular and gynaecological products. Since the Gedeon Richter is one of the few companies in the world with a comprehensive range of gynecological products, for professionals and patients is widely known as a reliable partner when it comes to health care of women.
Gynaecological therapy is an extremely important area for Richter. The company has several decades of unparalleled experience in this area. Thanks to development and expansion, Richter currently offers one of the widest ranges of gynaecological products in the world, including oral contraceptives and contraceptive devices, emergency contraceptives, hormone replacement therapy, osteoporosis products and antifungal preparations. Offering therapeutic solutions for every age group, the product range was further extended in 2012 with an innovative drug for the treatment of uterine myomas. With an acquisition in 2016 Richter also established its presence in the area of female fertility.